Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Xencor ( (XNCR) ) has shared an announcement.
On May 5, 2026, Xencor held a conference call to discuss data on its TL1A-focused autoimmune portfolio, highlighting final Phase 1 results for XmAb942 in healthy participants and preclinical characterization of bispecific candidate XmAb412 presented at Digestive Disease Week 2026. The company positioned XmAb942 and XmAb412 as potentially best-in-class TL1A-directed biologics for inflammatory bowel disease, emphasizing a Phase 2b trial in ulcerative colitis, a first-in-human study of XmAb412 targeted for the third quarter of 2026, and a broader 2026–2027 clinical readout schedule across its oncology and immunology pipelines, underscoring ambitions to capture share in the fast-growing global biologics market for IBD.
Xencor showcased how its XmAb engineering platforms and Xtend Fc technology aim to deliver higher potency, longer-acting subcutaneous TL1A therapies that may improve efficacy and dosing convenience over first-generation competitors. Management framed the TL1A franchise as a central growth driver within a projected multibillion-dollar IBD biologics market, with survey data indicating strong physician interest in anti-TL1A agents as first- or second-line advanced therapies and reinforcing Xencor’s bid for a leading position in this emerging class.
The most recent analyst rating on (XNCR) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.
Spark’s Take on XNCR Stock
According to Spark, TipRanks’ AI Analyst, XNCR is a Neutral.
The score is held down primarily by weak financial performance (revenue collapse to $0 in 2025, large losses, and heavy cash burn). Technicals provide some support with moderately positive momentum, while valuation is constrained by ongoing losses (negative P/E). Corporate events introduce additional revenue uncertainty (royalty dispute and collaboration termination), keeping the overall outlook cautious.
To see Spark’s full report on XNCR stock, click here.
More about Xencor
Xencor, Inc. is a clinical-stage biopharmaceutical company specializing in protein engineering, leveraging its XmAb platforms to design antibody and protein therapeutics for oncology and autoimmune diseases. The company focuses on rapid prototyping of XmAb candidates, supported by a strong cash position of about $611 million as of December 31, 2025, and partnerships that include multiple commercialized and late-stage medicines.
Average Trading Volume: 814,851
Technical Sentiment Signal: Sell
Current Market Cap: $979.8M
For a thorough assessment of XNCR stock, go to TipRanks’ Stock Analysis page.